Abstract: A Time And Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease from Belgium

 

Abstract: A Time And Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease from Belgium

In patients with bone metastases from solid tumours, denosumab (Dmab) subcutaneous (SC) injection represents an alternative formulation to zoledronic acid (Zol) intravenous (IV) infusion and a superior efficacy for skeletal-related events prevention. This observational Time and Motion study estimated time endpoints associated with Dmab SC injection and Zol IV use as monotherapy.